share_log

藥明生物：澄清公告

WUXI BIO: CLARIFICATION ANNOUNCEMENT

香港交易所 ·  Feb 13 17:37
Summary by Moomoo AI
药明生物（WuXi Biologics (Cayman) Inc.）於2024年2月14日發布澄清公告，回應美國議員於2024年2月12日的信函，該信函提及药明生物。公司澄清，其並非無錫藥明康德新藥開發股份有限公司的子公司，並指出信函中的相關陳述失實。药明生物強調為獨立運營的上市公司，並重申不會對美國或其他國家的國家安全構成風險。公司表示將繼續遵守合規經營原則及相關法律法規，致力於全球醫療健康服務。公告由董事長李革博士代表董事會發出，提醒股東及投資者審慎行事。
药明生物（WuXi Biologics (Cayman) Inc.）於2024年2月14日發布澄清公告，回應美國議員於2024年2月12日的信函，該信函提及药明生物。公司澄清，其並非無錫藥明康德新藥開發股份有限公司的子公司，並指出信函中的相關陳述失實。药明生物強調為獨立運營的上市公司，並重申不會對美國或其他國家的國家安全構成風險。公司表示將繼續遵守合規經營原則及相關法律法規，致力於全球醫療健康服務。公告由董事長李革博士代表董事會發出，提醒股東及投資者審慎行事。
WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) issued a Clarification Notice on February 14, 2024, in response to a letter from U.S. Members of Congress dated February 12, 2024, referring to pharmaceutical biologics. The Company clarified that it is not a subsidiary of Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd., and pointed out that the relevant statements in the letter are false. Pharma Biologics emphasizes being an independently operated listed company and reiterates that it does not pose a risk to national safety in the United States or other countries. The company stated that it will continue to adhere to the principles of business compliance and related laws and regulations and is committed to global healthcare services. The announcement was issued by the Chairman, Dr. Li Keung, on behalf of the Board, reminding shareholders and investors to exercise caution.
WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) issued a Clarification Notice on February 14, 2024, in response to a letter from U.S. Members of Congress dated February 12, 2024, referring to pharmaceutical biologics. The Company clarified that it is not a subsidiary of Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd., and pointed out that the relevant statements in the letter are false. Pharma Biologics emphasizes being an independently operated listed company and reiterates that it does not pose a risk to national safety in the United States or other countries. The company stated that it will continue to adhere to the principles of business compliance and related laws and regulations and is committed to global healthcare services. The announcement was issued by the Chairman, Dr. Li Keung, on behalf of the Board, reminding shareholders and investors to exercise caution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more